Study detail
RecruitingPhase 2
A Single-Arm, Multicenter Phase 2 Study of Neoadjuvant Pembrolizumab With Trastuzumab and Chemotherapy in Resectable HER2+ Esophagogastric Tumors
Memorial Sloan Kettering Cancer Center
Summary
The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.
Description
Eligible patients will receive 8 peri-operative cycles of pembrolizumab and trastuzumab with chemotherapy (fluoropyrimidine/oxaliplatin doublet for patients initially enrolled and subsequently FLOT \[5-fluorouracil, oxaliplatin and docetaxel\] followed by pembrolizumab and trastuzumab maintenance to complete 1 total year of therapy.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers